(i) To continue to characterise the clinical subphenotypes of ALS and to further elucidate the observed clinical and genetic overlap between ALS and neuropsychiatric disorders by detailed study of endophenotypes in first and second degree relatives.
(ii) To identify heterogeneous disease subcohorts based on genomic signatures, including those that overlap between ALS and neuropsychiatric illness.
(iii) To continue to utilise our recently developed neural network based technologies to characterise clinical subgroups based on network disruption at disease onset and during progression, and by developing our existing technologies as biomarkers for enrolment, stratification and outcome in early clinical agents with multiple mechanisms of action.
(iv)To develop novel and robust mathematical and statistical strategies to analyse and model our multimodal datasets.
SFI & Research Motor Neuron